Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience
Another Boost For AI
Executive Summary
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.
You may also be interested in...
AI/ML Grows In Importance, Holds Promise in mRNA
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.